Article thumbnail

Evaluation of Two Models for Human Topoisomerase I Interaction with dsDNA and Camptothecin Derivatives

By Gary S. Laco

Abstract

Human topoisomerase I (Top1) relaxes supercoiled DNA during cell division. Camptothecin stabilizes Top1/dsDNA covalent complexes which ultimately results in cell death, and this makes Top1 an anti-cancer target. There are two current models for how camptothecin and derivatives bind to Top1/dsDNA covalent complexes (Staker, et al., 2002, Proc Natl Acad Sci USA 99: 15387–15392; and Laco, et al., 2004, Bioorg Med Chem 12: 5225–5235). The interaction energies between bound camptothecin, and derivatives, and Top1/dsDNA in the two models were calculated. The published structure-activity-relationships for camptothecin and derivatives correlated with the interaction energies for camptothecin and derivatives in the Laco et al. model, however, this was not the case for several camptothecin derivatives in the Stacker et al. model. By defining the binding orientation of camptothecin and derivatives in the Top1/dsDNA active-site these results allow for the rational design of potentially more efficacious camptothecin derivatives

Topics: Research Article
Publisher: Public Library of Science
OAI identifier: oai:pubmedcentral.nih.gov:3166174
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles

Citations

  1. (1995). A novel suicide substrate for DNA topoisomerases and site-specific recombinases.
  2. (2001). A structural model for the ternary cleavable complex formed between human topoisomerase I, DNA, and camptothecin.
  3. (1996). Alteration of DNA primary structure by DNA topoisomerase I. Isolation of the covalent topoisomerase IDNA binary complex in enzymatically competent form.
  4. (2004). Analysis of human topoisomerase I inhibition and interaction with the cleavage site +1 deoxyguanosine, via in vitro experiments and molecular modeling studies.
  5. (1989). Arrest of replication forks by drugstabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin.
  6. (1985). Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I.
  7. (1990). Camptothecinstabilized topoisomerase I-DNA adducts cause premature termination of transcription.
  8. (2001). Characterization of a novel topoisomerase I mutation from a camptothecinresistant human prostate cancer cell line.
  9. (1998). Crystal structures of human topoisomerase I in covalent and noncovalent complexes with DNA.
  10. (1995). Differential stabilization of eukaryotic DNA topoisomerase I cleavable complexes by camptothecin derivatives.
  11. (1988). DNA topoisomerase-targeting antitumor drugs can be studied in yeast.
  12. (2002). Human topoisomerase I inhibition: Docking camptothecin and derivatives into a structure-based active site model.
  13. (1985). Hydrogen bonding and biological specificity analyzed by protein engineering.
  14. (1986). Hydrogen bonding and specificity. Fluorodeoxy sugars as probes of hydrogen bonding in the glycogen phosphorylase-glucose complex.
  15. (1989). Mapping in vivo topoisomerase I sites on simian virus 40 DNA: Asymmetric distribution of sites on replicating molecules.
  16. (2008). Next generation topoisomerase I inhibitors: Rationale and biomarker strategies.
  17. (1989). On the mechanism of topoisomerase I inhibition by camptothecin: Evidence for binding to an enzyme-DNA complex.
  18. (1966). Plant antitumor agents. I. The isolation and structure of camptothecin. A novel alkaloidal leukemia and tumor inhibitor from camptotheca acuminata.
  19. (1992). Reduced intracellular drug accumulation in the absence of p-glycoprotein (mdr1) overexpression in mitoxantrone-resistant human mcf-7 breast cancer cells.
  20. (2008). Role of a tryptophan anchor in human topoisomerase I structure, function and inhibition.
  21. (1999). Role of the 20-hydroxyl group in camptothecin binding by the topoisomerase I-DNA binary complex.
  22. (2010). Structural and dynamical effects induced by the anticancer drug topotecan on the human topoisomerase I - DNA complex.
  23. (2005). Structures of three classes of anticancer agents bound to the human topoisomerase I-DNA covalent complex.
  24. (1991). Synthesis of water-soluble (aminoalkyl)camptothecin analogues: Inhibition of topoisomerase I and antitumor activity.
  25. (2002). The hydrogen bond in the solid state. Angew Chem Int Ed 41: 48–76. Evaluation of Human Topoisomerase
  26. (2002). The mechanism of topoisomerase I poisoning by a camptothecin analog.
  27. (2004). The polar hydrophobicity of fluorinated compounds.
  28. (2003). Towards new anticancer drugs: A decade of advances in synthesis of camptothecins and related alkaloids.
  29. (2001). Tumor cell death induced by topoisomerase-targeting drugs.